Perspectives · Human capital

The Staffed Asset

How Europe’s care workforce will shape deal flow, diligence and value creation in the coming years

Corryk · September 2026

Capital is not in short supply in European healthcare. Committed dry powder, trade balance sheets and lender appetite remain deep, and well-funded bidders routinely compete for the same assets. Increasingly, the variable that separates a thesis that compounds from one that stalls is a different one: whether the people who deliver the care — dentists, nurses, GPs, vets, care workers, radiographers, pharmacists — can be retained, replaced and grown at the cost and pace the model assumes. This analysis is about that variable. It does not argue that human capital matters more than capital; it argues that human capital is the input most often under-diligenced and mispriced, and it maps — market by market, subsegment by subsegment — where a workforce constraint quietly supports a valuation and where it quietly erodes one.

Every healthcare investor has a demand story. Europe is ageing; chronic disease is rising; the 75-plus population — the heaviest users of almost every service discussed here — is the fastest-growing cohort on the continent. That story is real, and the charts confirm it in projection form: the old-age dependency ratio of the median EU market rises from 34 today to 50 by 2050. Demand, in other words, is close to a certainty.

Supply is not. The same demographic wave that swells the queue of patients is thinning the ranks of the people paid to treat them. The clinicians who will retire over the next decade were trained in cohorts set thirty years ago; the students who might replace them are capped by numerus-clausus rules, training-place budgets and the simple fact that you cannot manufacture a specialist in less than a decade. Where the shortfall is filled by workers trained abroad, the supply has become hostage to visa regimes and mutual-recognition politics that have grown markedly less friendly. And in the lowest-paid, highest-turnover corners of the sector, the constraint is not training at all — it is that a care worker can often earn as much in retail.

For the acquirer, this asymmetry — near-certain demand, contingent supply — is the whole game. It determines which roll-ups can actually be executed, because you cannot integrate a clinic you cannot staff. It sets the true ceiling on organic growth. It decides whether wage inflation is a passing line item or a structural margin tax. And, less obviously, it governs deal flow itself: the retirement of a generation of sole practitioners is the single largest source of sell-side supply in fragmented healthcare, and it is arriving on a schedule we can already read in the age data.

What follows is a map of where the workforce will help you and where it will hurt you, so that the scarcity can be priced on purpose rather than discovered after completion.

— Corryk

In brief

Three unifying principles frame the argument.

One — demand is a demographic near-certainty; supply is contingent, and in most markets already committed to shortfall. The old-age dependency ratio of the median EU market rises from 34 in 2024 to 50 by 2050 on Eurostat’s baseline projection; in Italy it reaches 61, in Spain 59 (Exhibit 2). Nothing in the workforce data rises to meet it. The clinicians who will retire this decade are already counted — 44% of Italy’s doctors and 41% of Poland’s are aged 55 or over — within or approaching the typical retirement band (Exhibit 3) — and the students who might replace them are capped by training budgets a decade upstream. You can raise a fund in months; you cannot raise a cohort of specialists in under ten years.

Two — workforce scarcity is two-sided for deals. It manufactures sell-side flow and it taxes buy-side margins, often in the same market. The retirement of a generation of sole-practitioner dentists, GPs, opticians and vets is the largest single source of sell-side supply in fragmented care — a succession wave that hands consolidators their pipeline of targets. The very same scarcity, once inside the platform, shows up as wage inflation, agency-staffing leakage and a hard ceiling on how fast beds, chairs and lists can actually be filled. The force that fills your deal pipeline empties your staff rota.

Three — the scarce input is rarely the one on the tin. Headline density flatters. Italy has among the most practising doctors per capita of any market we cover (535 per 100,000) and the oldest — a retirement cliff hidden inside apparent abundance. The United Kingdom looks comfortable on the age data (just 14% of doctors are 55-plus) precisely because it imports its way out: 38% of its doctors and 23% of its nurses were trained abroad (Exhibit 7), a supply that mutual-recognition and visa policy can throttle overnight. And the binding constraint differs by subsegment: for doctors, dentists and vets it is training capacity; for care workers it is wages (a nurse is paid below the average wage in six of our markets, a care worker below it almost everywhere); for the import-reliant it is politics.

In the coming years the European care sector will not be short of buyers or capital; it will be short of clinicians — and pricing that scarcity deliberately, subsegment by subsegment, is where the analytical advantage now lies.

The macro case

1 · The human-capital lens

Put a healthcare asset through the standard model and the workforce enters as a cost line — salaries, a wage-inflation assumption, perhaps an agency-staffing footnote. That treatment made sense when labour was elastic. It sits less easily in a decade when the binding input is frequently the clinician rather than the capital. The lens we propose is narrow and practical: for every asset, ask whether its workforce can be retained at the assumed cost, replaced when it turns over, and grown at the rate the plan requires. Those three verbs sit underneath almost every value-creation lever in care — occupancy, list size, chair utilisation, throughput, de-novo roll-out — and each has a workforce denominator.

This is not a claim that people matter more than money. Capital availability still decides who competes for an asset and at what cost of financing. It is a claim about where the mispricing lives. The property, the payor mix, the regulatory licence and the EBITDA bridge are typically underwritten to a decimal point; the workforce is more often carried as a headcount schedule and a wage assumption. That difference in granularity is where the analytical room is — on entry (a labour cliff the seller may not have surfaced), through the hold (margin pressure that is easy to underestimate), and on exit (a subsegment where labour has become the moat).

The cross-market picture builds along the six questions, and they resolve very differently across subsegments — because the same country can be a supply haven for pharmacists and a supply desert for care workers in the same postcode.

2 · The all-Europe map: scarcity against demand

Start with the single frame that organises the analysis (Exhibit 1, on the cover). On the horizontal axis, practising physicians per 100,000 people — supply, with the axis inverted so that scarcer markets sit to the right. On the vertical, the projected rise in the old-age dependency ratio to 2050 — demand growth. The upper-left region is where thin clinical supply meets the fastest-rising demand: the tightest labour markets on the continent, and the places where organic capacity cannot be added without importing or poaching staff. It is also, not coincidentally, where the consolidation logic is strongest, because when you cannot build capacity you must buy it.

Two cross-sections give the supply backdrop. On doctors (Exhibit 4), Italy tops the table at 535 practising physicians per 100,000 — but hold that number — it is the oldest such workforce in Europe. The UK (335) and Belgium (337) sit at the bottom, roughly a third below Italy. On nurses (Exhibit 5) the spread is even wider and tells a different story: Norway (1,560), Ireland (1,300) and Germany (1,200) run rich, while Spain (636) and Italy (650) sit barely half as deep — a structural nurse shortage their training pipelines are worsening rather than repairing.

The word “scarcity” in our title is deliberate. In a market where the clinical input is genuinely scarce and hard to reproduce, three things follow for the acquirer. First, incumbents with staffed, licensed capacity carry an option value that a greenfield competitor cannot cheaply replicate — the staffed clinic is worth more than the sum of its rooms. Second, that same scarcity is what pushes ageing independents to sell rather than recruit a successor, feeding the deal funnel. Third, scarcity has a dark side wherever the revenue line is capped — by a public tariff, a fixed list, or an occupancy ceiling — because then the scarce input bids up cost without a matching rise in price. The scarcity premium is the net of these: positive where the platform can price or roll up around the constraint, negative where the constraint simply taxes it. Which one applies is a subsegment question.

3 · The retirement cliff

The most legible number in workforce data is age, because it forecasts itself. A doctor who is 58 today is retired — or part-time and de-risking — by the middle of the next decade, and no policy lever changes that on an acquirer’s hold horizon. So the share of a workforce aged 55-plus is the closest thing to a leading indicator we have.

It is alarmingly high where it can least be afforded. Among physicians (Exhibit 3), Italy leads at 44% aged 55-plus, followed by Poland (41%), Switzerland (40%), and Belgium and Czechia (both 39%). France (35%), Germany (32%), Austria and Spain (33%) form a large second tier. This is the hidden qualifier: Italy’s chart-topping physician density is a stock about to shed its largest age band. A market can be simultaneously the best-supplied and the most exposed — abundance and cliff are not opposites when the abundance is grey.

Among nurses (Exhibit 6) the leaders are different — Denmark (30% aged 55-plus), Germany (25%), the Netherlands (25%) and Italy (25%) — and the implication is heavier, because nurses are the load-bearing wall of hospitals, care homes and increasingly primary care. Where a quarter to a third of the nursing stock retires within a decade against the demand curve in Exhibit 2, the arithmetic does not close on domestic training alone.

Why the cliff is, for parts of the sector, an opportunity. The retirement wave is also the deal engine of fragmented care. Across dentistry, optometry, physiotherapy, primary care and veterinary, the typical seller is an owner-operator in their late 50s or 60s with no partner to buy them out and a practice whose value is trapped in their own goodwill. That is the classic consolidation set-up, and the age data tell you it is not a one-off but a decade-long tailwind of forced sellers. The same cliff that threatens a care home’s rota hands a dental group its acquisition pipeline. The analysis keeps this duality in view: ageing is a supply threat and a deal-flow gift, and which one dominates is set by the subsegment’s ownership structure and revenue model.

4 · Import-dependent talent: the supply politics can move

Where the domestic pipeline cannot fill the gap, markets import clinicians. That is not a weakness in itself — it has kept several health systems standing — but it converts a share of the workforce into a policy-exposed asset, one that visa rules, salary thresholds and mutual-recognition agreements can expand or choke with a stroke. For an acquirer underwriting a five-year hold, the foreign-trained share is therefore a risk parameter, not a curiosity. One clarification, because the figure is easy to over-read: the exposure is not that a market’s existing foreign-trained clinicians suddenly leave. It is that the continuous replenishment the system runs on can be throttled — and a healthcare workforce must be replenished every year, because ordinary attrition, part-timing and the retirement cliff drain the stock continuously. A system that fills a large share of its annual intake from abroad is exposed the moment that intake is restricted, even if today’s roster is perfectly secure. The stock is stable; the flow is the risk.

The concentrations are remarkable (Exhibit 7). On doctors, Norway (44%), Ireland (41%), Switzerland (40%) and the UK (38%) now source close to half their physicians from abroad; Sweden (28%) is not far behind. On nurses the standout is Ireland at 54% — the Irish register contains more nurses trained outside Ireland than inside it — with Switzerland (27%) and the UK (23%) next. At the other end sit near-autarkic systems: Italy imports 1% of its doctors and 5% of its nurses; Poland 4% and under 1%; the Netherlands and Czechia similarly low. These are not better or worse — they are differently exposed. The import-reliant markets can lose supply to a policy change abroad or at home; the self-contained ones can only lose it to their own retirement cliff, with no import valve to open.

Why this is now a first-order diligence item. The last five years have seen the UK add and then repeatedly re-tune health-and-care visa rules and salary floors; Germany court foreign nurses through recognition fast-tracks; and source countries themselves — from the WHO’s “red list” of under-staffed health systems to India and the Philippines — assert more control over outflows. For a care platform in Ireland or the UK, a staffing plan that leans on an uninterrupted international intake carries a political risk that is easy to leave unpriced. It can be modelled directly: what is the cost, and the achievable pace, of replacing the marginal imported hire domestically? In the most exposed markets the honest answer is “slowly, and dearly.”

The two macro risks interact. A market with a low retirement cliff and low import-reliance (rare) is genuinely durable. A low cliff bought with high imports — the UK, Norway — is durable only as long as the border stays open. A high cliff with low imports — Italy, Poland — has no valve at all: the domestic pipeline is the only lever, and it is a decade long.

5 · The cost spiral: what the sector pays the workers it most needs

Wage inflation is the mechanism by which scarcity reaches the P&L. Because pay levels are not comparable across currencies and systems, we use a dimensionless measure — remuneration as a multiple of the national average wage — which is both fair across borders and directly relevant to hiring: it tells you how attractive a clinical job is against the local outside option, and how much room there is for it to be bid up.

For doctors the multiple is high and, in most systems, defended (Exhibit 9): specialists earn roughly 2–4× the average wage in most markets — led by Ireland (4.2×) and, on older data, Austria (4.6×) — with Norway the outlier low at 1.75×. The interesting stress is not here but one rung down. GPs are paid strikingly differently relative to their peers (Exhibit 10): Germany (4.0×) and Switzerland (2.9×) reward family medicine richly, while the UK sits last at 1.73× — a partial explanation for the British GP-partner recruitment crisis and, by extension, why so many UK primary-care lists are coming up for sale.

The sharpest finding is at the base of the pyramid. Registered nurses are paid below the national average wage in the UK (0.88×), Switzerland (0.85×), Sweden (0.99×), Finland and Italy (0.94×) and France (0.97×) — Exhibit 11. A profession paid under the local median is a profession with a permanent outside-option problem: every hospitality or retail wage settlement pulls at it. Below nurses sit care workers, paid at or near the statutory minimum almost everywhere, which is why their turnover runs at 20–30% a year. For any labour-intensive care asset — where staff can be 55–65% of revenue — a one-turn move in this ratio is the difference between the model working and not. The cost question is not “what do we pay” but “how far below the local alternative are we, and for how long can that hold.”

6 · The pipeline: under-filling in the wrong places

Everything above is a stock; the pipeline is the flow that replenishes it. Graduates per 100,000 people per year is the cleanest cross-market read on domestic self-sufficiency, and it underfills precisely where the stock is thinnest and oldest.

On doctors (Exhibit 12), Ireland (25 per 100,000) and Denmark (21) train richly; Norway (10.8), France (11.3) and Germany (12.2) train least — and Norway and (on the specialist side) France then plug the gap with imports, closing the loop back to import-dependence. On nurses (Exhibit 13) the dispersion is enormous and damning for the South: Switzerland trains 110 nurses per 100,000 a year, Norway 84, Finland 74 — while Italy trains 17 and Poland 20, against nursing stocks that are already the thinnest and, in Italy’s case, among the oldest in Europe. A market cannot import its way to 50 old-age dependency on 17 new nurses per 100,000. This is the clearest structural short in the entire dataset.

Combine the two flows — domestic training and import-reliance — and you get a pipeline-risk map (Exhibit 14). The dangerous quadrant is top-left: a thin domestic pipeline and heavy dependence on imported doctors, so that supply is neither home-grown nor politically secure. Norway sits closest to it. The comfortable quadrant, bottom-right, pairs a deep domestic pipeline with low import-reliance — the genuinely self-sufficient systems. Most markets fall in between, which is the honest picture: partial self-sufficiency, topped up by a politically contingent import.

Finally, the one contemporaneous read on tightness: the health-and-social-work job-vacancy rate (Exhibit 15), which says how hard it is to hire today. The Netherlands (4.2%), Norway (3.4%) and Austria (3.1%) run hottest; France and Germany sit mid-pack (2.7–2.9%). The low readings in Spain, Poland and Romania (all ≤0.8%) should be read with care: they reflect genuine labour-market slack in some cases and thinner vacancy reporting in others, and — crucially — a low vacancy rate against a collapsing pipeline (Spain, Italy) is not comfort, it is the quiet before the retirement cliff bites. We treat vacancy as a coincident indicator to be read against the leading ones (age and pipeline), never on its own.

Subsector deep-dives

Each deep-dive follows the same arc: the supply read (density, ageing, pipeline), the demand overlay, and the deal thesis — where the workforce constraint supports a valuation and where it erodes one. The through-line: subsegments built on ageing sole-practitioners convert scarcity into deal flow; subsegments built on salaried rotas against a capped tariff convert it into margin risk.

7 · Dental, optical & physiotherapy — the succession trade

These three clinician-led subsegments share a structure tailor-made for consolidation: highly fragmented ownership, a founder-operator whose goodwill is the enterprise value, and an age curve that guarantees a decade of forced sellers. The workforce question here is unusually friendly to the acquirer — but only in the markets where scarcity is real enough to give the platform pricing power.

Dental

Practising-dentist density (Exhibit 16) spreads from Norway (88 per 100,000), Germany (86) and Italy (82) at the top to the UK (51) and Ireland (48) at the bottom — roughly 40% below the leaders. Now overlay training (Exhibit 17): the UK trains just 1.9 dentists per 100,000 a year, Italy 1.5, the Netherlands 1.6, Switzerland 1.5 — against Spain’s 3.8 and Germany’s 3.0. A market that is both thinly supplied and thinly trained — the UK is the textbook case — is one where a chair, once staffed and licensed, carries scarcity value, and where the NHS-contract exodus has additionally created a wave of principals looking to exit. This is the most-worked consolidation theatre in European care for a reason.

Deal thesis (dental). Scarcity is constructive here. It supplies the sellers (ageing principals with no successor), it protects the platform from greenfield competition (you cannot open a chair you cannot staff), and in private-pay mixes it supports price. The workforce risks to underwrite are two: associate-dentist wage inflation in the tightest markets (UK, Ireland), which can outrun a fee book still partly tethered to public tariffs; and clawback if a departing principal takes list loyalty with them — a retention-engineering problem the best groups solve with earn-outs and clinical autonomy. Spain and Germany, better-trained and better-supplied, are lower-scarcity, lower-pricing-power roll-ups — still viable, but the edge is operational, not labour-driven.

Optical & physiotherapy

Optometry has the same owner-operator succession structure with a retail overlay; registrable-optical density is available for fewer markets but the roll-up logic mirrors dental, with the added lever of product margin. Physiotherapy (Exhibit 18) is more variable: Germany (240 per 100,000) and Belgium (228) are richly supplied — scarcity is a weak ally there — while Italy (106) and Ireland (119) are thinner. The physio thesis leans less on scarcity pricing and more on demand: an ageing population is a musculoskeletal-demand machine, and physio is a low-capital, high-fragmentation buy-and-build where the constraint is finding practice managers, not practitioners, in the well-supplied core.

8 · Veterinary — scarcity meets the pet boom

Veterinary is the subsegment where a workforce shortage and a demand boom have collided most violently, which is why it has drawn the most aggressive consolidation of all (the IVC Evidensia, VetPartners and Mars-Veterinary-Health platforms among them). Two datasets tell the story.

Supply (Exhibit 19) is thin and uneven: Spain (77 vets per 100,000) and Denmark (73) run richest; Sweden (25) and France (31) run less than half as deep. The UK (46) sits mid-table but lost a meaningful slice of EU-trained vets after Brexit — a live illustration of the import-dependence risk playing out in a single subsegment. Demand is a function of pets, and here the non-obvious geography matters: pet ownership is highest in Central and Eastern Europe — Poland is the most dog-owning market in the EU (49% of households), Romania the most cat-owning (48%), Czechia close behind (Exhibit 20) — markets that Western vet consolidators have barely touched.

Plot the two together (Exhibit 21) and the tightest quadrant — many pets, few vets — is where demand most outruns the ability to serve it. That is simultaneously the most attractive place to own capacity and the hardest place to grow it, which is the veterinary paradox in miniature: the shortage that makes the asset valuable is the same shortage that caps its throughput and bids up its wage bill.

Deal thesis (veterinary)

Constructive, with a margin caveat. Scarcity supplies the sellers (retiring practice owners), and pet-humanisation supports private price in a way a public tariff never could — the rare care subsegment where the operator, not a payor, sets the fee. But veterinary has learned the corrosive side too: burnout, attrition and a well-documented vet-wage spiral have compressed the margins of the first-generation roll-ups, and consumer-protection scrutiny of consolidator pricing has arrived in the UK. The workforce edge now: platforms that fix retention (rota design, clinical autonomy, vet-nurse skill-mix) rather than simply buying revenue. And the whitespace: the CEE demand map (Poland, Czechia, Romania) against near-zero consolidated penetration — the clearest “demand-rich, supply-building” frontier in the dataset.

9 · Elderly, residential & home care — where scarcity turns corrosive

If dental and veterinary are where the workforce constraint helps the acquirer, long-term care is where it hurts — and understanding the difference is most of what matters. Here labour is not an input to the product; labour is the product. Staff are 55–65% of revenue, the revenue line is frequently capped by a public fee or a local-authority rate, and the workforce is the lowest-paid and least stable in the entire sector.

The demand case is the strongest here and needs no embellishment: this subsegment serves the 75-plus cohort, and the old-age dependency ratio of the median EU market rises by half by 2050 (Exhibit 2). Skills for Care, the sector’s workforce development body, projects adult-social-care posts must grow 27% — roughly 470,000 additional posts — by 2040 simply to keep pace (Skills for Care). Occupancy demand is not the question. The question is whether anyone can be hired to meet it.

The supply signals are uniformly adverse. Nurse pay sits below the average wage across most of the region (Exhibit 11) and care-worker pay clusters at the statutory minimum, so the sector competes for staff against retail and hospitality and frequently loses. Turnover runs at 20% in Denmark, 23% in France and 30% in Ireland (Exhibit 22) — a re-hiring treadmill that is itself a large, recurring cost. And the nursing stock that anchors the clinical end of care is among the oldest in Europe (Denmark 30%, Germany 25% aged 55-plus). Where the vacancy rate is already hot — the Netherlands (4.2%), Norway (3.4%) — the ceiling on new capacity is being hit today.

Deal thesis (long-term care)

Corrosive scarcity — underwrite the rota, not just the beds. In this subsegment the workforce constraint caps the very thing the model sells (occupied, staffed beds and delivered care hours) and simultaneously inflates its largest cost. The failure mode is well-known: a home is registered for 60 beds but can safely staff 48, so the “occupancy upside” in the model is unreachable, and the gap is plugged with agency staff at 1.5–2× cost, and the margin bridge collapses. A careful underwrite prices fillable capacity, not licensed capacity; treats agency-staffing dependence as a leverage-like risk; and pays up for operators who have genuinely cracked retention (fixed rotas, career ladders, sponsorship pipelines) rather than those reporting a headline margin that a single wage settlement can erase. The real-estate value can be real and separable; the operating margin is a workforce bet, and it is the harder half.

10 · Primary care (GP) — the partnership cliff

Primary care sits between the two poles. Its economics resemble dental — owner-operator practices, succession-driven sell-side — but its revenue is usually public, which imports the tariff-cap risk of care. The result is a subsegment being reshaped less by demand than by the collapse of a labour model: the independent GP partnership.

GP density (Exhibit 23) must be read with a heavy comparability caveat — national definitions of “GP” differ sharply, and France’s high figure reflects its counting of médecins généralistes rather than a genuine surfeit — so we lean on the pay and age signals instead. Two stand out. First, the doctor age cliff (Exhibit 3) falls heavily on primary care: in Italy, France and much of the South, a large share of the family-medicine stock is 55-plus, and rural single-hander practices are retiring with no incoming partner. Second, pay relativity (Exhibit 10) is doing visible damage at the margin: the UK GP earns just 1.73× the average wage, the lowest in the set and a fraction of the German (4.0×) or Swiss (2.9×) family doctor. When the partnership no longer pays enough to justify the risk and hours, partners hand back contracts or sell — and a pipeline of lists comes to market.

Deal thesis (primary care)

Succession-driven, tariff-constrained. The deal flow is real and demographically guaranteed — the partnership model is unwinding fastest where pay relativity is worst (UK) and where the age cliff is steepest (Southern Europe). The value-creation edge is a skill-mix one: the platforms that thrive substitute scarce GP time with nurses, pharmacists and advanced-practice roles — which is only possible where the nurse stock and scope-of-practice rules allow it. That makes primary-care roll-ups a bet on the nursing supply as much as the medical one, and it is why the same play travels well in the Nordics and Netherlands (deep nurse supply, wide scope) and stalls in Italy and Spain (thin nurse supply). The risk to price: a public tariff that does not move with clinical wage inflation, squeezing exactly the practices you have just aggregated.

11 · Diagnostics & laboratories — the hedgeable shortage

Diagnostics is the subsegment where the workforce constraint is most hedgeable, which is precisely why it has attracted scale-driven consolidation with less of the labour-cliff anxiety that shadows care. The scarce inputs here are not doctors but technicians — biomedical scientists, radiographers, lab technologists — and the subsegment has two levers that the human-facing services lack: automation, which lowers labour intensity per test, and scale, which spreads scarce senior expertise across far more volume.

The relevant workforce metric is therefore not density but skill-mix headroom — how far a system can push work down from scarce, expensive roles to more available ones. Our cross-market proxy is nurses per physician (Exhibit 24): where it is high (Ireland 3.3, Belgium 3.3, Norway 3.1, the Netherlands 2.9), health systems have both the stock and the culture to substitute roles; where it is low (Italy 1.2, Spain 1.5) they do not. Radiographer supply is thin and unevenly measured — the UK reports about 70 per 100,000, Belgium 27 — and it is the genuine bottleneck in imaging, but it is one that networked reporting, tele-radiology and AI triage can stretch in a way that a care-home rota cannot be stretched.

Deal thesis (diagnostics & labs)

Scarcity is real but engineerable. The winning platforms treat the technician shortage as an automation-and-network problem, not a hiring problem: consolidate volume onto fewer, more automated hubs; centralise scarce senior reporting; and use skill-mix to keep the expensive grades on the work only they can do. That makes the subsegment less exposed to the retirement cliff than any human-delivered service — and it makes the workforce diligence question a different one: not “can we hire the staff” but “has this asset actually automated, or is its margin quietly dependent on cheap scarce labour that is about to reprice?” A lab reporting healthy margins on a manual process in a tight labour market is carrying the same hidden cost as an over-bedded care home.

12 · Pharmacy & hospitals — when the law is the constraint

Pharmacy: the roll-up map is drawn by ownership law, not density

Pharmacy is the subsegment where the workforce lens must yield to a regulatory one, and missing this has sunk more than one thesis. Pharmacist density varies widely — Italy (140 per 100,000), Belgium (128) and Spain (123) run rich; the Netherlands (22) runs a different, largely non-dispensing model (Exhibit 26) — but density barely matters to the deal, because whether you can consolidate pharmacies at all is a question of ownership law. Roughly half our markets reserve pharmacy ownership to licensed pharmacists and effectively ban corporate chains.

Exhibit 25 · Pharmacy ownership law: where a roll-up is possible

The legal perimeter matters before workforce supply: a fragmented market cannot form a platform where corporate ownership is prohibited.

The contrast could not be starker than Germany, where corporate pharmacy ownership is banned outright, versus the UK, where multiples (Boots, Well, Rowlands) have consolidated freely. A pharmacist-rich market with a pharmacist-only ownership rule — Spain, France — is a non-market for the corporate acquirer regardless of how attractive the density and demand look. This is the clearest case here of a constraint that no amount of capital or workforce advantage overcomes: the binding input is a statute.

The ownership-law constraint is not static, and it is moving against consolidators in the two subsegments they have worked hardest. In Germany, investor-owned dental chains built via Medizinische Versorgungszentren (MVZ) now face active political restriction of iMVZ in the Bundesrat — the roll-up window is narrowing. In France, corporate dental centres (centres de santé) drew tighter oversight after the Dentexia and Proxidentaire scandals. In the UK, NHS primary-care contracts are not freely transferable to corporates — a structural brake on GP roll-ups that dental and pharmacy do not face. The workforce may set the value of consolidated capacity; the ownership regime sets whether you are allowed to build it — and the regime is a live, moving diligence item, not a fixed backdrop.

Hospitals & specialist medical: the specialist bottleneck

Private hospital and specialist-clinic platforms sit on the richest headline supply — specialist density is high in Italy, Germany and the Nordics — but on the most exposed age curve. The specialists who staff private groups are drawn from the same pool retiring fastest (Exhibit 3), and unlike care workers they cannot be trained or substituted on any relevant horizon: a consultant is a fifteen-year asset. The binding constraint for a hospital roll-up is therefore specialist recruitment and retention — frequently solved by importing (returning to the import-dependence exposure for the UK, Norway and Switzerland) or by profit-share models that bind consultants to the platform. The demand tailwind is unquestioned; the workforce underwrite is whether the group’s specialist roster is contracted and young enough to survive the hold, or whether its EBITDA rests on a handful of senior names within a few years of retirement.

Implications

13 · The catalysts: what will move deal flow

Workforce dynamics are slow, but the events they trigger are datable. Below is our catalyst calendar — the human-capital developments most likely to move European care M&A over the coming years, and the direction of the push. Note that several are two-sided: the retirement wave that supplies sellers also tightens the labour market for the buyer who acquires them.

Exhibit 27 · The workforce catalyst calendar

The datable labour, regulatory and demographic events most likely to alter European healthcare deal flow.

14 · How scarcity reprices deals

Pull the subsectors together and a single organising rule emerges. Workforce scarcity is constructive for the acquirer wherever the subsegment is built on ageing owner-operators selling into private or mixed demand — there scarcity supplies both the sellers and the pricing power, and the moat is the staffed, licensed asset itself. Scarcity turns corrosive wherever the subsegment is built on salaried rotas against a capped tariff — there scarcity caps the sellable output and inflates the dominant cost, and no roll-up synergy repairs a rota that cannot be filled.

Exhibit 28 · When workforce scarcity is a moat — and when it is a tax

The constraint to underwrite by subsegment, and the distinction between constructive scarcity and a margin cap.

The buy-vs-build corollary. The deepest implication of a workforce constraint is that it changes the make-or-buy calculus of growth. When staff are abundant, a platform can grow greenfield and an acquirer pays only for assets in place. When staff are scarce, the staffed, licensed, retained team becomes the scarce asset — and the premium for buying occupied capacity over building empty capacity widens. That widening premium is the scarcity premium, and it is highest exactly where our supply exhibits are thinnest and our age curves oldest. The corollary for the corrosive subsegments is the mirror image: there, the scarcity premium can go negative — licensed capacity you cannot staff is worth less than its bricks, and the disciplined buyer pays below asset value for it.

15 · Country scorecards

A one-glance read of each market across the six questions, scored relative to the European field (not against each other in absolute terms). “Tighter” = more acute workforce constraint. This is a supply-risk map, not a deal-attractiveness ranking — a tight market can be highly attractive (scarcity value) or highly dangerous (margin cap) depending on the subsegment.

Exhibit 29 · Country scorecards: the workforce underwrite by market

A relative read of supply, ageing, import dependence, pipeline and hiring pressure across the European field.

Cell colour: darker = more constrained mid lighter = looser. Tertiles across the cross-market field per metric.

Scoring: each cell is High / Mid / Low relative to the cross-market distribution for that metric (tertiles). “Ageing” = % of physicians aged 55+; “Import-dep” = foreign-trained physician share; “Pipeline gap” = inverse of medical + nursing graduates per 100k; “Density” = physician density vs median (Low density = tighter). Blank cells = no comparable series published for that market (UK vacancy is absent from Eurostat; OECD practising-density anchors are unavailable for several CEE/Alpine markets).

16 · The bottom line

Capital is not the scarce input in European care; its abundance is exactly why the workforce has become such an interesting place to look. When every bidder can fund the deal, more of the differentiation sits in the diligence. The demand side of this sector is well understood — the ageing-population case is one every investor in it already has. The supply side has had less attention, because it is harder: it requires reading age curves, training flows, pay relativities, import-dependence and ownership law together, at subsegment grain, in seventeen different institutional settings.

The reward for doing so is not a forecast of who wins. It is a discipline: to price a labour cliff on entry rather than discover it in year three; to tell the difference between a market where scarcity is a moat and one where it is a tax; to know that a licensed care bed you cannot staff is worth less than its bricks, and a staffed dental chair in a training-short market is worth more than its fit-out. You can wire a data room in a weekend. You cannot wire a workforce — and in the coming years, that fact will do more to sort European care returns than any move in the cost of capital.

— Corryk

Comments, corrections or questions on this article: perspectives@corryk.com.